Genesis Biotechnology Group Executive and Leadership Team

Christopher Dillon, the Chief Operating Officer - GD3 at Genesis Biotechnology Group, directs the operational execution of the company's research and development initiatives. Overseeing the implementation and delivery of basic science products, Dillon ensures that diagnostic essays and drug discovery projects meet stringent quality standards and timelines. This leadership role involves optimizing internal processes and resource allocation to support Genesis Biotechnology Group's core mission. By managing the day-to-day operational flow, Christopher Dillon directly contributes to the company's capacity for innovation and its ability to bring critical research products to market. The operational scope encompasses ensuring efficient workflow from initial research phases through to product delivery, thereby reinforcing the company's position in the New Jersey research landscape.

Raymond Poon, the President at Genesis Biotechnology Group, provides overarching strategic direction and executive leadership. Poon guides the company's vision, ensuring alignment across all functional areas to achieve its objectives in basic science product development, including diagnostic essays and drug discovery. This role involves fostering key relationships with stakeholders, driving corporate strategy, and overseeing the organization's financial health and growth trajectory. By setting the strategic course, Raymond Poon ensures that Genesis Biotechnology Group remains at the forefront of scientific research and development. The leadership encompasses championing the company's mission, making critical decisions regarding resource allocation, and steering the organization towards sustained success and market impact within the biotechnology sector. Poon's executive oversight is fundamental to the company's operational and strategic advancement.

Bridgette Ballard, the President, Sales & Business Development Genesis Clinical Diagnostics at Genesis Biotechnology Group, spearheads the commercial strategy and market expansion for diagnostic solutions. Ballard directs all sales initiatives and cultivates strategic business partnerships to drive revenue growth and broaden the reach of Genesis Clinical Diagnostics' offerings. This leadership position involves identifying new market opportunities, developing effective sales channels, and ensuring customer satisfaction. By focusing on robust business development, Bridgette Ballard strengthens the company's market presence and facilitates the adoption of its diagnostic essays and drug discovery products. The scope of responsibility includes leading the sales team, managing client relationships, and aligning commercial activities with the overall corporate mission. Ballard's expertise is crucial for translating scientific advancements into tangible market success.

Stephanie Berry, the Chief Human Resources Officer at Genesis Biotechnology Group, architects the human capital strategy essential for driving scientific innovation. Berry oversees all aspects of talent management, employee relations, and organizational development, ensuring a robust workforce capable of advancing the company's research objectives. This critical function involves cultivating a culture that supports groundbreaking work in diagnostic essays and drug discovery. By developing and implementing comprehensive HR policies, Stephanie Berry ensures compliance and fosters an environment conducive to scientific excellence. The strategic focus includes attracting and retaining top-tier scientific talent, managing compensation and benefits, and promoting professional growth within the organization. Berry's leadership ensures that Genesis Biotechnology Group's most valuable asset – its people – are aligned with the company's mission and equipped to achieve its research and development goals.